People · Operator
Named in public records as an officer, director or promoter · active 2008–2023 · Pharmaceuticals, Retailing, Other, Manufacturing
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Apnimed, Inc. | — | Pharmaceuticals | Series C | $321.8M | $121.6M | 2018 |
| Tetraphase Pharmaceuticals Inc | — | Pharmaceuticals | Series C | $64.7M | $350.8M | 2009 |
| Customink, Llc | — | Retailing | Series B | $41.1M | $6.5M | 2013 |
| Zikani Therapeutics, Inc. | — | Pharmaceuticals | Series A | $31.7M | $232.3M | 2015 |
| Stonemor Partners Lp | — | Other | Series A | $12.9M | $194.9M | 2010 |
| Sequella Inc. | — | Pharmaceuticals | Seed | $10.6M | $24.0M | 2008 |
| Holganix, LLC | — | Other | Seed | $3.9M | $16.6M | 2023 |
| Danforth Pewterers Ltd | — | Manufacturing | Pre-Seed | $870K | $7.3M | 2009 |
Lawrence Miller at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Lawrence Miller on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Gerald Chan | 1 | 13 |
| Robert Weisskoff | 1 | 12 |
| John G. Freund | 1 | 6 |
| Joseph Zakrzewski | 1 | 6 |
| Robert Allen | 1 | 6 |
| Douglas Cole | 1 | 5 |
| Vikas Goyal | 1 | 5 |
| Raj Parekh | 1 | 5 |
| Ted Leonsis | 1 | 5 |
| Bradley Rotter | 1 | 4 |
| Markus Goebel | 1 | 4 |
| Kevin Harper | 1 | 4 |
| Henry Skinner | 1 | 4 |
| Andrew Myers | 1 | 4 |
| L. Patrick Gage | 1 | 3 |
| Mary Szela | 1 | 3 |
| David Lubner | 1 | 3 |
| Katie Langrock | 1 | 2 |
| Sumit Aggarwal | 1 | 2 |
| Karl D. Handelsman | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.